Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation
Phase: PHASE3
Conditions: Sepsis Syndrome
Sponsor: Louisiana State University Health Sciences Center in New Orleans

 
Use of a Live Attenuated Vaccine as an Immune-based Preventive 
Against COVID-19-associated Sepsis 
    
 
NCT04475081 
 
Study Protocol 
 
Last approval date: 7/19/23 
 
Upload date: 10/7/24 
 
 

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021

Approved -- Protocol Number: 1246 -- Version Number: 49 -- Approved on Aug 26, 2021